Home Angiogenesis Src

Src inhibitors

Src kinase which associates with various intracellular membranes, where it catalyzes the transfer of phosphate from ATP to a tyrosine residue within proteins is an non-receptor class of tyrosine kinases including Src, Fyn, Yes, Fgr, Hck, Lyn, Lck and Blk. Src plays an important role in both receptor-tyrosine-kinase-mediated proliferation and transformation of the cell to a tumor phenotype. Src is phosphorylated and activated by the growth factors binding to growth factor receptors including VEGFR, PDGFR, c-met receptors, ErbB family receptors and interleukin 6 (IL-6) receptors. Activated Src transduces a signal via phosphorylation of the adaptor protein Shc to the cascade that involves Ras and the mitogen-activated protein kinase (MAPK) family member, extracellular regulated kinase (Erk). This induces transcription of the early gene c-myc and increases DNA synthesis. Src can activate signal transducer and activator of transcription 3 (STAT3) via Src and Erk kinase and induce cell transformation.

Other Angiogenesis Related Inhibitors

FGFR HIF Bcr-Abl Syk VDA FLT3 FAK BTK ANGPTL FLT

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S1021 Dasatinib (BMS-354825) Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Cancer Cell, 2025, S1535-6108(25)00070-4
Mil Med Res, 2025, 12(1):83
Nat Commun, 2025, 16(1):4069
Verified customer review of Dasatinib (BMS-354825)
S7565 WH-4-023 WH-4-023 (KIN001-112, KIN112, Dual LCK/SRC inhibitor) is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Stem Cell Res Ther, 2025, 16(1):527
Stem Cell Res Ther, 2025, 16(1):617
Commun Biol, 2025, 8(1):125
Verified customer review of WH-4-023
S1490 Ponatinib (AP24534) Ponatinib is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively. Ponatinib (AP24534) inhibits autophagy.
Nat Commun, 2025, 16(1):471
Theranostics, 2025, 15(8):3589-3609
J Exp Clin Cancer Res, 2025, 44(1):290
Verified customer review of Ponatinib (AP24534)
S5254 Dasatinib hydrochloride Dasatinib hydrochloride (BMS-354825) is the hydrochloride salt form of dasatinib, an inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Clin Transl Med, 2024, 14(5):e1660
Cell Death Dis, 2024, 15(8):603
iScience, 2024, 27(10):110862
S1010 BIBF 1120 (Nintedanib) Nintedanib is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.
Nat Commun, 2025, 16(1):471
Cell Death Dis, 2025, 16(1):196
Eur J Pharmacol, 2025, 1005:178058
Verified customer review of BIBF 1120 (Nintedanib)
S1396 Resveratrol (trans-Resveratrol) Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases（LOX, IC50=2.7 μM）, kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis.
Aging Cell, 2025, e70075
Biomed Pharmacother, 2025, 190:118393
Breast Cancer Res, 2025, 27(1):186
Verified customer review of Resveratrol (trans-Resveratrol)
S8161 ON123300 ON123300 is a potent and multi-targeted kinase inhibitor with IC50 of 3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM and 11nM for CDK4, Ark5/NUAK1, PDGFRβ, FGFR1, RET (c-RET), and Fyn, respectively.
Cell Rep Med, 2025, S2666-3791(25)00231-9
Cell Rep, 2024, 43(7):114446
J Cell Sci, 2021, jcs.258685
S2391 Quercetin (Sophoretin) Quercetin, a natural flavonoid present in vegetables, fruit and wine, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4-5.4 μM. Quercetin induces mitophagy, apoptosis and protective autophagy. Phase 4.
Alzheimers Res Ther, 2025, 17(1):176
Cell Mol Life Sci, 2025, 82(1):164
Virol Sin, 2025, S1995-820X(25)00102-6
Verified customer review of Quercetin (Sophoretin)
S1006 Saracatinib (AZD0530) Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and is potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). It induces autophagy and is in Phase 2/3.
J Clin Invest, 2025, e177599
Cell Rep, 2025, 44(1):115109
Cell Rep, 2025, 44(7):115972
Verified customer review of Saracatinib (AZD0530)
S7782 Dasatinib Monohydrate Dasatinib Monohydrate (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
iScience, 2024, 27(10):110862
bioRxiv, 2023, 2023.05.11.540170
bioRxiv, 2023, 2023.05.11.540170
Verified customer review of Dasatinib Monohydrate

Signaling Pathway Map